Summary:
Symbiotec Pharmalab IPO closed on August 27 with strong demand, receiving 14.59 times subscription overall. QIBs subscribed 6.27 times, NIIs 39.61 times, retail investors 8.65 times and employees 9.86 times. The sharp final-day surge was led by institutional and NII participation. Allotment is scheduled for August 28, with listing expected on September 1, 2026.
Symbiotec Pharmalab, the Indore-based pharmaceutical and biotechnology company, closed its final day of bidding on August 27, 2026, for its ₹1,757 crore mainboard IPO. The issue wrapped up with strong overall demand of 14.59 times, driven by a sharp institutional and NII surge in the closing session.
IPO Details
| Detail | Information |
|---|---|
| Issue Size | ₹1,757 crore (fresh issue ₹150 crore + OFS ₹1,607 crore) |
| Price Band | ₹938–₹988 per share |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 |
| Face Value | ₹2 per share |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Registrar | MUFG Intime India Pvt Ltd |
| Book-Running Lead Managers | JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory |
Category-wise Breakdown on Final Day
| Category | Shares Offered/Reserved | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutional Buyers (QIBs) | 37,39,872 | 2,34,42,705 | 6.27 |
| Non Institutional Investors | 28,04,904 | 1,10,88,950 | 39.61 |
| — NII (bids above ₹10 lakh) | 18,69,936 | 8,10,84,240 | 43.36 |
| — NII (bids ₹2–10 lakh) | 9,34,968 | 3,00,64,710 | 32.09 |
| Retail Individual Investors (RIIs) | 65,44,778 | 5,65,65,340 | 8.65 |
| Employees | 35,377 | 3,48,750 | 9.86 |
| Total | 1,31,24,929 | 10,14,85,745 | 14.59 |
Data as of 27-Aug-2026, 12:30 PM IST, sourced from NSE Consolidated Bid Details (nseindia.com).
Symbiotec Pharmalab IPO - Final Subscription Status
As of the close of bidding on August 27, 2026, the issue received bids for 10,14,85,745 shares against 1,31,24,929 shares on offer, taking overall subscription to 14.59 times. Non-Institutional Investors led all categories at 39.61 times, followed by Employees at 9.86 times, Retail Individual Investors at 8.65 times, and Qualified Institutional Buyers at 6.27 times.
What the Final Day Numbers Indicate
The sharp jump in NII and QIB subscription in the closing session — up from 10.59 times and 0.59 times respectively on Day 3 — is the classic mainboard pattern, where institutional and larger HNI investors place the bulk of their bids only after gauging demand through the earlier sessions. Within the NII category, the above-₹10-lakh bracket (43.36x) outpaced the ₹2–10 lakh bracket (32.09x), pointing to particularly aggressive participation from larger applicants in the final hours. Retail subscription at 8.65 times, while more modest by comparison, still reflects solid individual investor interest in a company with specialised API capabilities and consistent revenue and profit growth.
Symbiotec Pharmalab IPO - Timetable
| Event | Date |
|---|---|
| Anchor Bid Date | August 21, 2026 |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Allotment Finalisation | August 28, 2026 |
| Refund/Demat Credit | August 31, 2026 |
| Listing Date | September 1, 2026 |
| Listing Exchanges | BSE, NSE |
Should You Apply for Symbiotec Pharmalab IPO?
Incorporated in 2002 and headquartered in Indore, Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology, and complex injectables. The company's business spans corticosteroid and steroidal-hormone active pharmaceutical ingredients, along with nutritional ingredients and specialty products, serving both domestic and international regulated and emerging markets. Revenue grew 15% year-on-year to ₹872.26 crore in FY26, with profit after tax rising 14% to ₹109.90 crore.
Investors considering the issue should weigh the company's specialised API capabilities, steady revenue and profit growth, and exposure to regulated international markets against risks typical of the pharmaceutical API business, such as regulatory compliance requirements across geographies and pricing pressure in commoditised segments. As with any IPO, the decision should be based on individual risk appetite, investment horizon, and a review of the RHP rather than subscription numbers alone.
How to Apply for Symbiotec Pharmalab IPO
Bidding has now closed for the Symbiotec Pharmalab IPO. Investors who applied during the window from August 24–27, 2026, can check their allotment status once the basis of allotment is finalised on August 28, 2026.
How to Check Symbiotec Pharmalab IPO Subscription Status
How to check Symbiotec Pharmalab IPO Subscription Status on NSE website
- Visit the NSE IPO issue information page (nseindia.com).
- Search for "Symbiotec Pharmalab" or enter the symbol SYMBIOTEC.
- Select "Consolidated Bid Details" from the dropdown to view category-wise subscription data.
How to check Symbiotec Pharmalab IPO Subscription Status on BSE website
- Visit the BSE IPO page (bseindia.com).
- Navigate to the "Active IPO" or "IPO Bidding" section.
- Select "Symbiotec Pharmalab Limited" from the list of issues.
- View category-wise and overall subscription figures for the full bidding window.
How to check Symbiotec Pharmalab IPO Subscription Status on Ventura?
Ventura clients can track subscription status for the Symbiotec Pharmalab IPO within the IPO section of the Ventura app or web platform, alongside category-wise bid data and upcoming allotment updates.
IPO Subscription History
Previous Day Subscription
Subscription built up steadily over the first three days of bidding, reaching 4.75 times overall by Day 3 on the back of NII and employee demand, before a sharp final-day surge pushed NII subscription past 39 times and QIB subscription above 6 times.
Conclusion
Symbiotec Pharmalab's IPO closed on a strong note, with overall subscription reaching 14.59 times on the back of a robust final-day surge in institutional and NII demand. With allotment due on August 28 and listing scheduled for September 1, 2026, investors who applied will need to check their allotment status closer to those dates through the registrar, exchange websites, or their broking platform.
